{"title":"食管癌手术治疗患者的静脉血栓栓塞:一项基于省级人群的研究。","authors":"Gileh-Gol Akhtar-Danesh, Noori Akhtar-Danesh, Yaron Shargall","doi":"10.1055/s-0042-1750378","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective</b> Venous thromboembolism (VTE) is a major cause of morbidity and mortality in surgical patients. Surgery for esophageal cancer carries a high risk of VTE. This study identifies the risk factors and associated mortality of thrombotic complications among patients undergoing esophageal cancer surgery. <b>Methods</b> All patients in the province of Ontario undergoing esophageal cancer surgery from 2007 to 2017 were identified. Logistic regression identified VTE risk factors at 90 days and 1 year postoperatively. A flexible parametric survival analysis compared mortality and survival up to 5 years after surgery for patients with and without a postoperative VTE. <b>Results</b> Overall 9,876 patients with esophageal cancer were identified; 2,536 (25.7%) underwent surgery. VTE incidence at 90 days and 1 year postoperatively were 4.1 and 6.3%, respectively. Patient factors including age, sex, performance status, and comorbidities were not associated with VTE risk. VTE risk peaked at 1 month after surgery, with a subsequent decline, plateauing after 6 months. Adenocarcinoma was strongly associated with VTE risk compared with squamous cell carcinoma (SCC) (odds ratio [OR] 2.53, 95% confidence interval [CI] 1.38-4.63, <i>p</i> = 0.003). VTE risk decreased with adjuvant chemotherapy (OR = 0.58, 95% CI 0.36-0.94, <i>p</i> = 0.028). Postoperative VTE was associated with decreased survival at 1 and 5 years (hazard ratio = 1.57, 95% CI 1.23-2.00, <i>p</i> < 0.001). <b>Conclusion</b> Esophageal cancer patients with postoperative VTE have worse long-term survival compared with those without thrombotic complications. Adenocarcinoma carries a higher VTE risk compared with SCC. Strategies to reduce VTE risk should be considered to reduce the negative impacts on survival conferred by thrombotic events.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":" ","pages":"e168-e176"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273319/pdf/","citationCount":"2","resultStr":"{\"title\":\"Venous Thromboembolism in Surgically Treated Esophageal Cancer Patients: A Provincial Population-Based Study.\",\"authors\":\"Gileh-Gol Akhtar-Danesh, Noori Akhtar-Danesh, Yaron Shargall\",\"doi\":\"10.1055/s-0042-1750378\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective</b> Venous thromboembolism (VTE) is a major cause of morbidity and mortality in surgical patients. Surgery for esophageal cancer carries a high risk of VTE. This study identifies the risk factors and associated mortality of thrombotic complications among patients undergoing esophageal cancer surgery. <b>Methods</b> All patients in the province of Ontario undergoing esophageal cancer surgery from 2007 to 2017 were identified. Logistic regression identified VTE risk factors at 90 days and 1 year postoperatively. A flexible parametric survival analysis compared mortality and survival up to 5 years after surgery for patients with and without a postoperative VTE. <b>Results</b> Overall 9,876 patients with esophageal cancer were identified; 2,536 (25.7%) underwent surgery. VTE incidence at 90 days and 1 year postoperatively were 4.1 and 6.3%, respectively. Patient factors including age, sex, performance status, and comorbidities were not associated with VTE risk. VTE risk peaked at 1 month after surgery, with a subsequent decline, plateauing after 6 months. Adenocarcinoma was strongly associated with VTE risk compared with squamous cell carcinoma (SCC) (odds ratio [OR] 2.53, 95% confidence interval [CI] 1.38-4.63, <i>p</i> = 0.003). VTE risk decreased with adjuvant chemotherapy (OR = 0.58, 95% CI 0.36-0.94, <i>p</i> = 0.028). Postoperative VTE was associated with decreased survival at 1 and 5 years (hazard ratio = 1.57, 95% CI 1.23-2.00, <i>p</i> < 0.001). <b>Conclusion</b> Esophageal cancer patients with postoperative VTE have worse long-term survival compared with those without thrombotic complications. Adenocarcinoma carries a higher VTE risk compared with SCC. Strategies to reduce VTE risk should be considered to reduce the negative impacts on survival conferred by thrombotic events.</p>\",\"PeriodicalId\":22238,\"journal\":{\"name\":\"TH Open: Companion Journal to Thrombosis and Haemostasis\",\"volume\":\" \",\"pages\":\"e168-e176\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273319/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TH Open: Companion Journal to Thrombosis and Haemostasis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0042-1750378\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TH Open: Companion Journal to Thrombosis and Haemostasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1750378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
目的静脉血栓栓塞(VTE)是外科患者发病和死亡的主要原因。食管癌的手术有很高的静脉血栓栓塞风险。本研究确定了食管癌手术患者血栓性并发症的危险因素和相关死亡率。方法选取2007 - 2017年安大略省所有食管癌手术患者。Logistic回归在术后90天和1年确定静脉血栓栓塞的危险因素。一项灵活的参数生存分析比较了有和没有术后静脉血栓栓塞的患者术后5年的死亡率和生存率。结果共确诊食管癌9876例;2536例(25.7%)接受手术治疗。术后90天和1年静脉血栓栓塞发生率分别为4.1%和6.3%。患者因素包括年龄、性别、运动状态和合并症与静脉血栓栓塞风险无关。静脉血栓栓塞风险在手术后1个月达到顶峰,随后下降,6个月后趋于稳定。与鳞状细胞癌(SCC)相比,腺癌与静脉血栓栓塞风险密切相关(优势比[OR] 2.53, 95%可信区间[CI] 1.38-4.63, p = 0.003)。辅助化疗降低静脉血栓栓塞风险(OR = 0.58, 95% CI 0.36-0.94, p = 0.028)。术后静脉血栓栓塞与1年和5年生存率降低相关(风险比= 1.57,95% CI 1.23-2.00, p)结论食管癌术后静脉血栓栓塞患者的长期生存率较无血栓并发症患者差。与鳞状细胞癌相比,腺癌具有更高的静脉血栓栓塞风险。应考虑降低静脉血栓栓塞风险的策略,以减少血栓形成事件对生存的负面影响。
Venous Thromboembolism in Surgically Treated Esophageal Cancer Patients: A Provincial Population-Based Study.
Objective Venous thromboembolism (VTE) is a major cause of morbidity and mortality in surgical patients. Surgery for esophageal cancer carries a high risk of VTE. This study identifies the risk factors and associated mortality of thrombotic complications among patients undergoing esophageal cancer surgery. Methods All patients in the province of Ontario undergoing esophageal cancer surgery from 2007 to 2017 were identified. Logistic regression identified VTE risk factors at 90 days and 1 year postoperatively. A flexible parametric survival analysis compared mortality and survival up to 5 years after surgery for patients with and without a postoperative VTE. Results Overall 9,876 patients with esophageal cancer were identified; 2,536 (25.7%) underwent surgery. VTE incidence at 90 days and 1 year postoperatively were 4.1 and 6.3%, respectively. Patient factors including age, sex, performance status, and comorbidities were not associated with VTE risk. VTE risk peaked at 1 month after surgery, with a subsequent decline, plateauing after 6 months. Adenocarcinoma was strongly associated with VTE risk compared with squamous cell carcinoma (SCC) (odds ratio [OR] 2.53, 95% confidence interval [CI] 1.38-4.63, p = 0.003). VTE risk decreased with adjuvant chemotherapy (OR = 0.58, 95% CI 0.36-0.94, p = 0.028). Postoperative VTE was associated with decreased survival at 1 and 5 years (hazard ratio = 1.57, 95% CI 1.23-2.00, p < 0.001). Conclusion Esophageal cancer patients with postoperative VTE have worse long-term survival compared with those without thrombotic complications. Adenocarcinoma carries a higher VTE risk compared with SCC. Strategies to reduce VTE risk should be considered to reduce the negative impacts on survival conferred by thrombotic events.